Controlled delivery of peptides and proteins

Current Pharmaceutical Design

Volumn 13, Issue 1, 2007, Pages 99-117

  Degim, I Tuncer ^a   Çelebi, Nevin ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Controlled delivery; Peptide; Protein

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA INTERFERON; BETA INTERFERON; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEOXYRIBONUCLEASE; DESMOPRESSIN; DORNASE ALFA; EPTIFIBATIDE; GAMMA INTERFERON; GLUCOSYLCERAMIDASE; HIRUDIN; HUMAN GROWTH HORMONE; IMIGLUCERASE; INSULIN; IVERMECTIN; LEUPRORELIN; MICROSPHERE; MYELIN PROTEIN; NANOCAPSULE; NAPROXEN; NUTROPINE DEPOT; POLYGLACTIN; RECOMBINANT INTERLEUKIN 2; SALCATONIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BIOCOMPATIBILITY; BIODEGRADABILITY; BONE DISEASE; CARCINOMA; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG IMPLANT; DRUG POTENCY; ELECTROPORATION; EQUIPMENT DESIGN; GAUCHER DISEASE; HAIRY CELL LEUKEMIA; HEMOPHILIA; HEMOPHILIA B; HUMAN; HYDROGEL; IONTOPHORESIS; MICROCAPSULE; MICROEMULSION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STRUCTURE; RESPIRATORY TRACT DISEASE; REVIEW; SHORT STATURE; SINGLE DRUG DOSE; VIRUS INFECTION;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CAPSULES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG COMPOUNDING; DRUG IMPLANTS; DRUG STABILITY; ELECTROPORATION; EMULSIONS; HUMANS; HYDROGELS; IONTOPHORESIS; MICROSPHERES; MODELS, MOLECULAR; NANOCAPSULES; PROTEIN CONFORMATION; PROTEINS; SOLUBILITY;

EID: 33846138309     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207779313795     Document Type: Review

References (107)

1. Lee VHL. Changing needs in drug delivery in the era of peptide and protein drugs, In: Lee HHL Ed., Peptide Protein Delivery. Macel and Dekker Inc., New York, 1990; 1-57.
2. Silbart LK, Karen DF. Reduction of intestinal carcinogen absorption by carcinogen-specific secretory immunity. Science 1989; 243: 1462-1464.
3. Cleland JL. Protein delivery from biodegradable microspheres, In: Sanders LM, Hendren RW. Eds., Protein Delivery: Physical Systems. Plenium Press, New York, 1997; 1-39.
4. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Del Rev 2004; 56: 581-587.
5. Pillai O, Nair V, Panchagnula R. Transdermal iontophoresis of insulin: IV. Influence of chemical enhancers. Int J Pharm 2004; 269: 109-120.
6. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm 2001; 51: 93-109.
7. Pontiroli AE. Intranasal administration of calcitonin and of other peptides: studies with different promoters. J Cont Rel 1990; 13: 247-251.
8. Mackay M, Phillips J, Hastewell J. Peptide drug delivery: colonic and rectal absorption. Adv Drug Del Rev 1997; 28: 253-273.
9. Acartürk F, Degun Z, Degim T. Investigation of the absorption of insulin through vagina in rabbits, AAPS Annual Meeting and Exposition. 10-14 November, Toronto, Canada, 2002.
10. Degim Z, Degim T, Acartürk F, Erdogan D, Özogul C. Köksal M. Rectal administration of insulin-chitosan formulations: an experimental study in rabbits, Proceedings, 30th Annual Meeting & Exposition of the Controlled Release Society. July 19-23, Scotland, United Kingdom, 2003.
11. Smith PL. Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery. J Cont Rel 1997; 46: 99-106.
12. Wathm N. Peptide and protein delivery tops new survey of drug firm. Gen Eng News 1994; 14: 1.
13. Mackay M. Delivery of therapeutic peptides and proteins, In: Crommelin DJA, Schellekens H Eds., Development in Biotherapy: From Clone to Clinic, Kluwer Academic, Dordrecht, 1990; 315-342.
14. Machay M. Delivery of recombinant peptide and protein drugs. Biotech Gen Eng Rev 1990; 8: 251-278.
15. Mackay M, Phillips J, Hastewell J. Peptide drug delivery: colonic and rectal absorption. Adv Drug Del Rev 1997; 28: 253-273.
16. Gesellchen PD, Santerre RF. Synthesis of peptides and proteins by chemical and biotechnological means, In: Lee VHL Ed., Peptide and Protein Drug Delivery. Marcel and Dekker Inc., New York, 1991; 57-136.
17. Banga AK. Structure and analysis of therapeutic peptides and proteins. In Therapeutic Peptides and Proteins: Formulation, Processing and Delivery Systems. Technomic Publishing Co. Inc., Pennsylvania, 1995.
18. Denton JB, Konishi Y, Scheraga HA. Folding of ribonuclease A from a partially disordered conformation. Biochemistry 1982; 21: 5155-5163.
19. Sali, A, Shakhnovic E, Karplus M. Kinetics of protein folding-A lattice model study of the requirements for folding to the native state. J Mol Biol 1994; 235: 1614-1636.
20. Young L, Jernigan RL, Covell DG. A role for surface hydrophobicity in protein-protein recognition. Protein Science 1994; 3: 717-729.
21. Illum L, Fisher AN, Jabbal-Gill I, Davis SS. Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm 2001; 222: 109-119.
22. Wheatley MA, Chang M, Park E, Langer R. Coated alginate microspheres: factors influencing the controlled delivery of macromolecules. J Appl Pol Sci 1991; 43: 2123-2135.
23. Mi FL, Shyu SS, Lin YM, Wu YB, Peng CK, Tsai HY. Chitin/PLGA blend microspheres as a biodegradable drug delivery system: a new delivery system for protein. Biomaterials 2003; 24: 5023-5036.
24. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004; 274: 1-33.
25. Wua TJ, Huanga HH, Lana CW. Studies on the microspheres comprised of reconstituted collagen and hydroxyapatite. Biomaterials 2004; 25: 651-658.
26. Liu X, Sun O, Wang H, Zhang L, Wang JY. Microspheres of corn protein, zein, for an ivermectin drug delivery system. Biomaterials 2005; 26: 109-115.
27. Santiago N, Milstein S, Rivera T, Garcia E, Zaidi T, Hong H, et al. Oral immunization of rats with proteinoid microspheres encapsulating influenza virus antigens. Pharm Res 1993; 10: 1243-1247.
28. Herr G, Wahl D, Kussweyyer W. Osteogenic activity of bone morphogenic protein and hydroxyapatite composite implants. Ann Chir Gynaecol 1993; 82: 99-107.
29. Leach JB, Schmidt CE. Characterization of protein release from photocrosslinkable hyaluronic acid-polyethylene glycol hydrogel tissue engineering scaffolds. Biomaterials 2005; 26: 125-135.
30. Ribeiroa CC, Barriasa CC, Barbosaa MA. Calcium phosphate-alginate microspheres as enzyme delivery matrices. Biomaterials 2004; 25: 4363-4373.
31. Kompella UB, Lee VHL. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Del Rev 2001; 46: 211-245.
32. Zhang X, Wu D, Chu CC. Synthesis and characterization of partially biodegradable, temperature and pH sensitive DexMA/PNIPAAm hydrogels. Biomaterials 2004; 25: 4719-4730.
33. Kamath KR, Park K. Biodegradable hydrogels in drug delivery. Adv Drug Del Rev 1993; 11: 9-84.
34. Berkland C, Kipper MJ, Narasimhan B, Kim K, Pack D. Microsphere size, precipitation kinetics and drug distribution control drug release from biodegradable polyanhydride microspheres. J Cont Rel 2004; 94: 129-141.
35. Blanco-Prieto MJ, Campanero MA, Besseghir K, Heimgatner F, Gander B. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/ PLGA microspheres. J Cont Rel 2004; 96: 437-448.
36. Chia HH, Yang YY, Chung TS. Auto-catalyzed poly(ortho ester) microspheres: a study on their erosion and drug release mechanism, J Control Rel 2001; 75: 11-25.
37. Bourke SL, Kohn J. Polymers derived from the amino acid L-tyrosine: polycarbonates, polyarylates and copolymers with poly(ethylene glycol). Adv Drug Del Rev 2003; 55: 447-466.
38. Pulapura S, Li C, Kohn J. Structure-property relationships for the design of polyiminocarbonates. Biomaterials 1990; 11: 666-678.
39. Schachter DM, Kohn J. A synthetic polymer matrix for the delayed or pulsatile release of water-soluble peptides. J Cont Rel 2002; 78: 143-153.
40. Takenaga M, Yamaguchi Y, Kitagawa A, Ogawa Y, Mizushima, Y, Igarashi R. A novel sustained release formulation of insulin with dramatic reduction in initial rapid release. J Cont Rel 2002; 79: 81-91.
41. Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly-caprolactone microspheres and nanospheres: an overview. Int J Pharm 2004; 278: 1-23.
42. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Del Rev 2002; 54: 169-190.
43. Veronese FM, Marsilio F, Caliceti P, Filippis PD, Giunchedi P, Lora S. Polyorganophosphazene microspheres for drug release: polymer synthesis, microsphere preparation, in vitro and in vivo naproxen release. J Cont Rel 1998; 52: 227-237.
44. Lakshmi S, Katti DS, Laurencin CT. Biodegradable polyphos-phazenes for drug delivery applications. Adv Drug Del Rev 2003; 55: 467-482.
45. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Cont Rel 2003; 90: 261-280.
46. Hincal AA, Calis S, Microsphere preparation by solvent evaporation method, In: Wise DL. Ed., Handbook of Pharmaceutical Controlled Release Technology. Marcel Dekker Inc., New York, 2000; 329-344.
47. Bittner B, Morlock M, Koll H, Winter G, Kissel T. Recombinant human erythropoietin (rHEPO) loaded poly-(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microspheres characteristics. Eur J Pharm Biopharm 1998; 45: 295-305.
48. Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, et al. A month long effect from a single injection of microencapsulated human growth hormone. Nat Med 1996; 2: 795-799.
49. Genta I, Perugini P, Pavanetto F, Maculotti K, Modena T, Casado B, et al. Enzyme loaded biodegradable microspheres in vitro ex vivo evaluation. J Cont Rel 2001; 77: 287-295.
50. Fattal E, Couvreur P, Pecquet S. Oral tolerance induced by poly(lactide-co-glycolide) containing B lactoglobulin. Ann Pharm Fr 2002; 60: 44-49.
51. Mehta RC, Jeyanthi R, Calis S, Thanoo BC, Burton KW, DeLuca Biodegradable microspheres as depot system for parenteral delivery of peptide drugs. J Cont Rel 1994; 29: 375-384.
52. Zhou S, Deng X, He S, Li X, Jia W, Wei D, et al. Study on biodegradable microspheres containing recombinant interferon-alpha-2a. J Pharm Pharmacol 2002; 54: 1287-1292.
53. Yeh MK. The stability of insulin in biodegradable microparticles based on blends of lactide polymers and poly-ethylene glycol. J Microencapsul 2000; 7: 743-756.
54. Weert M, Hennink WE, Jiskoot W. Protein instability in PLGA microparticles. Pharm Res 2000; 17: 1159-1167.
55. Yeo Y, Basaran OA, Park K. A new process for making reservoir-type microcapsules using inkjet technology and interfacial phase separation. J Cont Rel 2003; 93: 161-173.
56. Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 2002; 19: 73-98.
57. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opp Sol State and Mat Sci 2002; 6: 319-327.
58. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Cont Rel 2000; 65: 261-269.
59. Lemoine D, Preat V. Polymeric nanoparticles as delivery system for influenza virus glycoproteins. J Cont Rel 1998; 54: 15-27.
60. Tobio M. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B 2000; 18: 315-323.
61. Fishbein I, Chorny M, Rabinovich L, Banai S, Gati I, Golomb G. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J Cont Rel 2000; 65: 221-229.
62. Watnasirichaikul S, Rades T, Tucker IG, Davies NM. Effects of formulation variables on characteristics of poly (ethylcyanoacrylate) nanocapsules prepared from w/o microemulsions. Int J Pharm 2002; 235: 237-246.
63. http://www.atrixlabs.com/ourtech/atrigel.cfm
64. Yewey GL, Duysen EG, Cox SM, Dunn RL. In: Sanders LM, Hendren RW Eds., Delivery of proteins from a controlled release injectable implant. Protein Delivery: Physical Systems. Plenium Press, New York, 1997; 93-118.
65. Wyatt TL, Saltzman WM. In: Sanders LM, Hendren RW Eds., Protein delivery from nondegradable polymer matrices. Protein Delivery: Physical Systems. Plenium Press, New York, 1997; 119-137.
66. http://www.indiana.edu/~health/norplant.html
67. Wyatt TL, Whaley KJ, Cone RA, Saltzman WM. Antigen-releasing polymer rings and microspheres stimulate mucosal immunity in the vagina. J Cont Rel 1998; 50: 93-102.
68. Wright JC, Leonard ST, Stevenson CL, Beck JC, Chen G, Jao RM, et al. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Cont Rel 2001; 75: 1-10.
69. Leoni L, Desai TA. Micromachined biocapsules for cell-based sensing and delivery. Adv Drug Del Rev 2004; 56: 211-229.
70. Rathi RC, Zentner GM. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. US Patent 6.004.573, 1999.
71. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, Oh H, et al. Biodegradable block colpolymers for drug delivery of proteins and water-insoluble drugs. J Cont Rel 2002; 72: 203-215.
72. Kim YJ, Choi S, Koh JJ, Lee M, Ko KS, Kim SW. Controlled release of insulin from injectable biodegradable triblock copolymer. Pharm Res 2001; 18: 548-550.
73. Celebi N, Erden N, Gönül B, Koz M. Effects of epidermal growth factor dosage forms on dermal wound strength in mice. J Pharm Pharmacol 1994; 46: 386-387.
74. Çelebi N, Alemdaroglu-Isbasar C, Degim Z, Erdogan D, Nacar A, Özogul C. The effects of EGF containing liposome formulations on burn wound healing: a histological study, Proceedings, European Conference on Drug Delivery and Pharmaceutical Technology. May 10-12, Sevilla, Spain, 2004.
75. Isbasar C, Degim Z, Celebi N. Development and in vitro evaluation of chitosan gel and liposome formulation of EGF, Proceedings, 30th Annual Meeting & Exposition of the Controlled Release Society, Scotland. July 19-23, United Kingdom, 2003.
76. Yetkin G, Celebi N, Agabeyoglu I, Gökcora N. The effect of dimethyl-β-cyclodextrin and sodium taurocholate on the nasal bioavailability of salmon calcitonin in rabbits. STP Pharma Sciences 1999; 9: 249-252.
77. Yetkin G, Celebi N, Ozogul C, Demiryürek AT. Enhancement of nasal absorption of salmon calcitonin in rabbits using absorption enhancer. STP Pharma. Sciences 2001; 11: 187-191.
78. Degim Z, Çelebi N, Sayan H, Babül A, Erdogan D, Take G. An investigation on skin wound healing in mice with a taurine-chitosan gel formulation. Amino Acids 2002; 22: 187-198.
79. Katakam M, Ravis WR, Banga AK. Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels. J Cont Rel 1997; 49: 21-26.
80. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm 1999; 184: 189-198.
81. Wenzel JGW, Balaji KSS, Koushik K, Navarre C, Duran SH, Rahe CH, et al. Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Cont Rel 2002; 85: 51-59.
82. Senel S, Kremer MJ, Kas S, Wertz PW, Hincal AA, Squier AA. Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials 2000; 21: 2067-2071.
83. Matsuzawa A, Morishita M, Takayama K, Nagai T. Absorption of insulin using water-in-oil-in-water emulsion from an enteral loop in rats. Biol Pharm Bull 1995; 18: 1718-1723.
84. Morishita M, Matsuzawa A, Takayama K, Isowa K, Nagai T. Improving insulin enteral absorption using water-in-oil-in-water emulsion. Int J Pharm 1998; 172: 189-198.
85. Onuki Y, Morishita M, Takayama K, Tokiwa S, Chiba Y, Isowa K, et al. In vivo effects of highly purified docosahexaenoic acid on rectal insulin absorption. Int J Pharm 2000; 198: 147-156.
86. Suzuki A, Morishita M, Kajita M, Takayama K, Isowa K, Chiba Y, et al. Enhanced colonic and rectal absorption of insulin using a multiple emulsion containing eicosapentaenoic acid and docosahexaenoic acid. J Pharm Sci 1998; 87: 1196-1202.
87. Onuki Y, Morishita M, Takayama K. Formulation optimization of water-in-oil-water multiple emulsion for intestinal insulin delivery. J Cont Rel 2004; 97: 91-99.
88. Cournarie F, Savelli MP, Bretez VRF, Vauthier C, Grossiord IL, Seiller M. Insulin-loaded W/O/W multiple emulsions: comparison of the performances of systems prepared with medium-chain-triglycerides and fish oil. Eur J Pharm Biopharm 2004; 58: 477-482.
89. Margreiter R. for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group, Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-746.
90. Tükyilmaz A. An investigation on the effects of epidermal growth factor on gastrointestinal system ulcers, PHD thesis, Gazi University, Faculty of Pharmacy, Departrnent of Pharmaceutical Technology. Ankara, 1998.
91. Celebi N, Tükyilmaz A, Gönül B, Ozogul C. Effects of epidermal growth factor microemulsion formulation on the healing of stress-induced gastric ulcers in rats. J Cont Rel 2002; 83: 197-210.
92. Celebi N, Türkyilmaz A, Gönül B, Alkan-Onyuksel H. In: Hincal A, Kas HS, Eds., Physical characterization and stability of a micro-emulsion for potential oral administration of a peptide, Biomedical Science and Technology, Recent Developments in the Pharmaceutical Sciences. Plenium Press, New York, 1998; 65-72.
93. Yetkin G, Celebi N, Ozer C, Gönül B, Ozogul C. The healing effect of TGF-α on gastric ulcer induced by acetylsalicylic acid in rats. Int J Phárm 2004; 277: 163-172.
94. Cilek A. Development of insulin containing microemulsion formulations and in vivo evaluations, Master Degree thesis, Gazi University, Faculty of Pharmacy, Department of Pharmaceutical Technology. Ankara, 2001.
95. Cilek A, Celebi N, Ocak F, Tay A. Oral absorption of recombinant insulin from microemulsion in rats, EUFEPS World Conference on Drug Absorption and Drug Delivery Benefiting from New Biology and Informatics. Copenhagen, Denmark, June 18-20, 2001; Proceedings. Abstracts, p. 81-82.
96. Celebi N, Cilek A, Ocak F, Krisnada A. Preparation and characterization of microemulsion using lecithin as surfactants for oral administration of insulin, Pharmacy and Pharmaceutical Sciences World Congress. 61st International Congress of FIP, 1-6 Sept 2001; Singapore, Abstracts, p.72.
97. Dogru ST, Calis S, Oner F. Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro -in vivo evaluation. J Clin Pharm Ther 2000; 25: 435-443.
98. Degim T, Pugh WJ, Hadgraft J. Effect of ion complexants on the iontophoresis of salbutamol. Int J Pharm 1998; 167: 229-231.
99. Degim IT, Ilbasmis S, Dundaroz R, Oguz Y. Reverse iontophoresis-I: a non-invasive technique for measuring blood urea level. Pediatr Nephrol 2003; 18: 1032-1037.
100. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Del Rev 2004; 56: 619-658.
101. Langkjaer J, Brange J, Grodsky GM, Guy RH. Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J Cont Rel 1998; 51: 47-56.
102. Kari B. Control of blood glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin. Diabetes 1986; 35: 217-221.
103. Pliquett UF, Gusbeth CA. Perturbation of human skin due to application of high voltage. J Bioelectrochem 2000; 51: 41-51.
104. Bodde HE, Brink IV, Koerten HK, Haan FHN. Visualization of in vitro percutaneous penetration of mercuric chloride transport though intercellular space versus cellular uptake though desmosomes. J Cont Rel 1991; 1: 227-236.
105. Jang HS, Kim HJ, Kim JM, Lee YS, Kim KL, Kim JA, et al. A novel ex vivo angiogenesis assay based on electroporation-mediated delivery of naked plasmid DNA to skeletal muscle. Mol Ther 2004; 9: 464-474.
106. Tollefsen S, Tjelle TE, Schneider J, Harboe M, Wiker HG, Hewinson G, et al. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 2002; 20: 3370-3378.
107. Mitragotri S, Kost J. Low-frequency sonophoresis. Adv Drug Del Rev 2004; 56: 589-601.